


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 		Application Number	09/835/298
		Filing Date	4/13/01
		First Named Inventor	Dahlen et al.
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
Sheet <u>1</u> of <u>3</u>	Attorney Docket Number	071949-5301	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>al</i>	A1	6756483		Bergmann et al.	06-29-2004	

U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
<i>al</i>	A2	WO	00/22439		B.R.A.H.M.S. Diagnostica GMBH	04-20-2000		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
<i>al</i>	A3	ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Section 2.3, p. e8.	
<i>al</i>	A4	ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction, "Overview of Acute Coronary Syndrome," pages 4 and 20.	

Examiner Signature	<i>Ch. K. Han</i>	Date Considered	11/19/07
--------------------	-------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	09/835/298
		Filing Date	4/13/01
		First Named Inventor	Dahlen et al.
		Group Art Unit	1641
		Examiner Name	Ann Y. Lam
(use as many sheets as necessary)		Attorney Docket Number	071949-5301
Sheet	2	of	3

NON PATENT LITERATURE DOCUMENTS			
Exami ner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	American College of Cardiology and the Joint European Society of Cardiology, <i>J. Am. Coll. Cardiol.</i> 36: 959-969 (2000), Albert et al., section entitled "II. Clinical Presentation," p. 960.	
	A6	Goetze <i>et al.</i> , "Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing," <i>Clin. Chem.</i> 48: 1035-42, 2002	
	A7	HASSAN et al., "Non-viable myocardium, documented by TL-201 SPECT, is a main determinant of the increase in the secretion of cardiac natriuretic peptides" <i>Medecine Nucleaire</i> , 2000, 24/6, pp 301-310 (Database EMBASE Accession No. 2001129199 and English language translation)	
	A8	Omland <i>et al.</i> , N-terminal Pro-B-Type natriuretic peptide and long-term mortality in acute coronary syndrome. <i>Circulation</i> 106: 2913-18 (2002)	
	A9	Rabbani, Editorials, "Acute coronary syndromes-Beyond Myocyte necrosis." <i>N. Engl. J. Med.</i> 345: 1057-59 (2001)	
	A10	Sagnella, "Measurement and importance of plasma brain natriuretic peptide and related peptides," <i>Ann. Clin. Biochem.</i> 38: 83-93, 2001	
	A11	Shimizu <i>et al.</i> , "Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system," <i>Clin. Chim. Acta</i> 305: 181-6, 2001	

Examiner Signature		Date Considered	1/19/07
-----------------------	--	--------------------	---------


<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>2</sup>Unique citation designation number. <sup>3</sup>See attached Kinds of U.S. Patent Documents. <sup>4</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/835/298
		Filing Date	4/13/01
		First Named Inventor	Dahlen et al.
		Group Art Unit	1641
Examiner Name	Ann Y. Lam		
Attorney Docket Number	071949-5301		
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
	A12	Silver <i>et al.</i> , "BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Disease," <i>CHF</i> 10[5 Suppl. 3]: 1-30 (2004)	

Examiner Signature		Date Considered	1/19/07
--------------------	---	-----------------	---------

<sup>8</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.